<DOC>
	<DOCNO>NCT01245348</DOCNO>
	<brief_summary>The purpose study validate SULT4A1-1 status stratification improve response atypical antipsychotic schizophrenia extend finding bipolar disorder .</brief_summary>
	<brief_title>Relative Effectiveness Schizophrenia Therapy Study</brief_title>
	<detailed_description>The total economic burden schizophrenia ( SZ ) U.S. estimate $ 60 billion annually . A large contributor economic burden chronic mental disorder , include bipolar disorder ( BPD ) , exacerbation symptom disability due lack drug efficacy . For disorder , clinician typically choose first line antipsychotic therapy without support diagnostic tool ; often , patient switch another drug less six month treatment due perceive patient clinician insufficient efficacy unacceptable side effect . Originally , sulfotransferase family 4A , member 1 ( SULT4A1 ) gene select biomarker interest SZ base result show association gene disease severity . Later , SULT4A1 gene status also associate well efficacy atypical antipsychotic ( e.g . Zyprexa® ( olanzapine ) Risperdal® ( risperidone ) ) , respect time discontinuation quantitative measure clinical improvement . In prospectively design , non-randomized retrospective study , recruit genotype subject schizophrenia bipolar disorder were/are new therapy four drug evaluation . By look retrospective prospective longitudinal medical pharmacy data store within integrated claim database , validate association SULT4A1 gene efficacy select atypical antipsychotic therapy .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Subjects ≥ 18 year age Subjects either confirmed diagnosis schizophrenia bipolar disorder subject self report schizophrenia bipolar disorder Subjects were/are new therapy olanzapine , risperidone , quetiapine ziprasidone Subjects willing able provide inform consent Subjects initially prescribe less generally accept minimally effective dose drug study Subjects Major Depressive Disorder ( MDD ) another psychotic disorder schizophrenia bipolar disorder Subjects catatonic schizophrenia Subjects moderate severe mental retardation Subjects refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>atypical antipsychotic</keyword>
	<keyword>adherence</keyword>
	<keyword>cost effectiveness</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>mental illness</keyword>
	<keyword>SULT4A1</keyword>
</DOC>